Attana Cell 200 - Bridging the gap between traditional biosensors and cell-based assays!
Drug development is costly and risky and the need for technologies that accelerate the process of drug discovery becomes increasingly urgent. This paper shows four instances of how the Attana Cell 200 biosensor provides data enhancing the ability to select the right drug candidates earlier in the process.
2011-03-03 09:40 March 3rd, 2011, Stockholm, Sweden – Attana AB, developer of biosensors, is proud to announce our participation in Today in America with Terry Bradshaw in their series on topics, trends, and issues related to “Improving Diagnostic Outcomes through Biosensor Technology” as part of the show’s “Medical Minutes” series.
2009-10-18 16:24 View article in Innovations in Pharmaceutical Technology (IPT), a brief overview of Attana's core business. http://www.iptonline.com/viewinn.asp?cat=2&article=285
2011-11-16 09:30 One efficient tool in the selection process is biochemical label‐free kinetic characterisation of interactions between candidate and target molecules. Information on association and dissociation rates and affinity is provided under purified conditions. However, the results obtained are often different compared to the affinity results obtained with cell based methods.
2011-05-31 09:00 Find out latest news, events and collaborations from Tecan- read the interview with Attana's Sales and Marketing Manager, Gabriela Suhoschi about Attana's collaboration with Tecan's on page 5!
2010-06-14 10:02 The Attana cell sensor chip with the cultivation lid and cell suspension added.
2011-03-02 09:00
Attana is featured in Today in America with Terry Bradshaw in their series on topics, trends, and issues related to “Improving Diagnostic Outcomes through Biosensor Technology” as part of the show’s “Medical Minutes” series. In the clip we find out why biological relevance is important and how it is possible to shorten the time between research initiation and new drug on the market.
Längd 5:00
2011-01-14 09:00
The Attana Cell 200 biosensor has the unique ability to determine label-free kinetics directly on the cell surface, therefore disclosing the full complexity of the interaction at a very early stage. By delivering biologically relevant information this early in the research process, The Attana Cell 200 minimizes costs and increases success during clinical trials.(produced by TTV AB)
Längd 1:24
Lägg till kommentarKommentaren sparades
Innan den publiceras måste den godkännas av Attana AB.